2025-12-07 - Analysis Report
Here's a comprehensive analysis of Natera Inc. (NTRA) based on the provided data.

**1. Return Rate Comparison and Alpha/Beta Analysis**

*   **Company Overview:** Natera Inc. is a diagnostics company specializing in cell-free DNA testing, primarily focusing on reproductive health and cancer diagnostics.
*   **Return Rate:**
    *   Natera (NTRA) Cumulative Return: 144.07%
    *   S&P 500 (VOO) Cumulative Return: 101.54%
    *   Divergence: Current: 43.6, Relative Divergence: 50.2
*   **Analysis:** Natera has significantly outperformed the S&P 500 over the analyzed period. The current divergence of 43.6 represents a notable difference in cumulative returns. A relative divergence of 50.2 indicates that the current divergence is around the midpoint of its historical fluctuation range relative to the S\&P 500.
*   **Alpha/Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | -10.0% | 70.1% | -34.0% | -0.2  | 1.3    |
| 2016-2018  | 22.0%  | 80.0% | 6.0%   | 0.1   | 2.0    |
| 2017-2019  | 50.0%  | 80.0% | 28.0%  | 1.0   | 4.8    |
| 2018-2020  | 186.0% | 80.5% | 163.0% | 1.1   | 14.1   |
| 2019-2021  | 96.0%  | 80.5% | 49.0%  | 1.6   | 13.2   |
| 2020-2022  | -77.0% | 80.5% | -76.0% | 0.1   | 5.7    |
| 2021-2023  | -194.0%| 76.6% | -195.0%| -1.1  | 8.9    |
| 2022-2024  | 8.0%   | 76.6% | -13.0% | -1.2  | 22.4   |
| 2023-2025  | 171.0% | 76.6% | 105.0% | 0.1   | 33.8   |

*   **Analysis:**
    *   **CAGR:**  The Compound Annual Growth Rate fluctuates significantly, showing periods of strong growth and sharp declines.
    *   **MDD:**  The Maximum Drawdown is consistently high, indicating significant volatility and potential risk.
    *   **Alpha:** Alpha values are highly variable, with periods of significant outperformance (positive alpha) and underperformance (negative alpha) relative to the market.
    *   **Beta:** Beta values vary from negative to positive indicating NTRA's correlation to market movements changes over time, with a higher Beta suggesting more volatility.
    *   **Cap(B):** Market capitalization growth, with recent positive trends.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 238.21
*   **Last Market Data:** Price: 244.55, Previous Close: 242.06, Change: 1.03
*   **Moving Averages:**
    *   5-day SMA: 237.656
    *   20-day SMA: 219.167
    *   60-day SMA: 191.4018
*   **Analysis:** The current price is above all three moving averages, suggesting a short-term and medium-term upward trend. The 5-day SMA being closest to the current price indicates more recent price stability compared to the more distant 20-day and 60-day SMAs. The small change from the previous close suggests a period of consolidation.

**3. Indicators Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 76.41 (Overbought)
*   **PPO:** 0.27 (Positive Momentum)
*   **Hybrid Signal:** Buy 100% of cash (4 shares - Very Safe - MRI:0.90), monthly invest 0.8%
*   **Recent Relative Divergence Change:** 1.7 (+) (Short-term Increase)
*   **Expected Return:** -46.4% (Negative expected return compared to S&P 500 over 2+ years)
*   **Analysis:**
    *   The MRI suggests a medium investment recommendation.
    *   The RSI indicates that the stock is currently overbought, which might suggest a potential pullback or consolidation.
    *   The positive PPO indicates that there is positive momentum in the stock price.
    *   The Hybrid signal recommends a specific allocation strategy, balancing risk and potential return.
    *   Recent increase in relative divergence indicates short-term upward momentum.
    *   The negative expected return compared to the S&P 500 is concerning for long-term investors.

**4. Recent News & Significant Events**

*   **[2025-12-06]** Share Offering and Lymphoma Data: This highlights potential dilution and ongoing research.
*   **[2025-12-05]** Insider Selling: Solomon Moshkevich selling shares could indicate a lack of confidence or personal financial planning. Steven Leonard Chapman also sold shares.
*   **[2025-12-04]** Valuation Assessment: Focuses on valuation after a recent rally.
*   **[2025-12-05]** Foresight Deal: Acquisition and financial implications (upfront payment and earnouts) may affect valuation.
*   **[2025-11-24]** Stock Up 3%: Positive movement noted.
*   **Analysis:**
    *   The news cycle is a mix of positive (acquisition, stock up) and negative (insider selling, valuation concerns) signals.
    *   The share offering mentioned in the first headline can lead to dilution, potentially affecting the stock price.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (~1.47 on a 1-5 scale)
*   **Opinions:** 19
*   **Target Price:** Avg: 237.05 / High: 280.00 / Low: 186.00
*   **Recent Rating Changes:** No changes listed.
*   **Analysis:**
    *   Strong buy consensus with a large number of opinions.
    *   The average target price is close to the current price, suggesting limited near-term upside according to analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출     |
|------------|--------|----------|
| 2025-11-07 | -0.64  | 0.59 B$  |
| 2025-08-08 | -0.74  | 0.55 B$  |
| 2025-05-09 | -0.50  | 0.50 B$  |
| 2024-11-12 | -0.26  | 0.44 B$  |
| 2025-11-07 | -0.26  | 0.44 B$  |

*   **Analysis:**
    *   The company has consistently reported negative EPS (Earnings Per Share) for the quarters presented, indicating ongoing losses.
    *   Revenue has been generally increasing, which is a positive sign. However, it hasn't translated into profitability.

**6. Financial Information**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.59B    | 64.91%        |
| 2025-06-30   | $0.55B    | 63.41%        |
| 2025-03-31   | $0.50B    | 63.12%        |
| 2024-12-31   | $0.48B    | 62.94%        |
| 2024-09-30   | $0.44B    | 61.79%        |

Capital and Profitability:

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $1.25B    | -6.99%    |
| 2025-06-30   | $1.25B    | -8.10%    |
| 2025-03-31   | $1.24B    | -5.40%    |
| 2024-12-31   | $1.20B    | -4.50%    |
| 2024-09-30   | $0.88B    | -3.60%    |

*   **Analysis:**
    *   Revenue is growing, as seen in the previous earnings analysis.
    *   Gross profit margins are strong, indicating efficient core operations.
    *   Equity is increasing, indicating financial stability.
    *   ROE is consistently negative, reinforcing the lack of profitability.

**7. Comprehensive Analysis (Summary)**

Natera (NTRA) has significantly outperformed the S&P 500. However, it carries substantial risk.

*   **Strengths:** Strong revenue growth, high gross profit margins, positive momentum as indicated by moving averages and the PPO, a "Strong Buy" analyst consensus, and innovative focus on reproductive health and cancer diagnostics.

*   **Weaknesses:** Consistent negative EPS and ROE indicate lack of profitability, high Maximum Drawdown indicating high volatility, negative expected return compared to the S&P 500, insider selling raising concerns, and potential dilution from share offerings.

*   **Overall:** The company's growth potential in the diagnostics market is apparent. However, its lack of profitability and high volatility make it a speculative investment. The overbought RSI suggests caution in the short term. The "Strong Buy" analyst consensus should be weighed against the negative financial performance and the insider selling. Potential investors should carefully consider their risk tolerance and investment horizon before investing in NTRA. The news of the Foresight deal and lymphoma data updates may provide additional insight into the company's trajectory.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.